Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03741127 · ClinicalTrials.gov registry record · Phase 1
Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
A Phase 1 study of Multiple Myeloma, sponsored by Poseida Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 13
- Study locations
NCT03741127: Active Phase 1 study of Multiple Myeloma, sponsored by Poseida Therapeutics.
NCT03741127 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by Poseida Therapeutics. The registered enrollment target is 100 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (82% lower). The trial reports 13 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03741127, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Poseida Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 13
- Study locations
Study Summary
Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.
Primary Outcome
Incidence and severity of treatment-emergent adverse events to evaluate the long-term safety of P-BCMA-101
Conditions Studied
Interventions
- DRUG Rimiducid may be administered as indicated
Study Locations (13)
California
- University of California Davis - Davis
- University of California, San Diego - San Diego
- University of California San Francisco - San Francisco
Maryland
- University of Maryland Greenebaum Comprehensive Cancer Center - Baltimore
- Johns Hopkins University - Baltimore
Tennessee
- Sarah Cannon Research Institute at Tennessee Oncology - Nashville
- Vanderbilt University Medical Center - Nashville
Colorado
- Colorado Blood Cancer Institute - Denver
Illinois
- University of Chicago - Chicago
Kansas
- University of Kansas Cancer Center - Westwood
Michigan
- Wayne State - Karmanos Cancer Institute - Detroit
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-10-29 |
| Est. Completion | 2032-11 |
| Phase | Phase 1 |
What the registry record for NCT03741127 still lists
NCT03741127 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Rimiducid may be administered as indicated is the first listed.
NCT03741127 lists 13 locations in 9 states (California, Maryland, Tennessee).
Frequently Asked Questions
What is clinical trial NCT03741127 about?
NCT03741127 is a clinical study titled "Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101". Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to as...
What is the current status of trial NCT03741127?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2018-10-29. Estimated completion is 2032-11.
What conditions does trial NCT03741127 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT03741127?
The interventions under investigation include: Rimiducid may be administered as indicated (DRUG).
Who is sponsoring clinical trial NCT03741127?
This trial is sponsored by Poseida Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03741127 being conducted?
This trial has 13 study locations across California, Colorado, Illinois, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03741127's enrollment target sits among peer trials
100 165th of 438 higher than 262 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI